Müller Norbert, Schennach Rebecca, Riedel Michael, Möller Hans-Jürgen
Hospital for Psychiatry & Psychotherapy, Ludwig-Maximilians-University, 80336 Munich, Germany.
Expert Rev Neurother. 2008 Apr;8(4):527-36. doi: 10.1586/14737175.8.4.527.
Major depressive disorder (MDD) is one of the most disabling disorders. Antidepressant pharmacotherapy is currently effective in approximately 70% of all treated cases; the potential superiority of a dual mechanism of pharmacological action (e.g., inhibiting the reuptake of serotonin and norepinephrine) is widely known. Duloxetine, a novel dual acting, selective serotonin and norepinephrine reuptake inhibitor, has demonstrated clinical efficacy in the treatment of MDD and general anxiety disorder (GAD). Duloxetine has been found to be safe and well tolerated, with mild-to-moderate adverse events, a favorable cardiovascular and sexual dysfunction profile, and minor influence on weight gain. The efficacy of duloxetine in the treatment of MDD has been established in randomized, double-blind, placebo-controlled studies. In addition to improving classical emotional symptoms of MDD, duloxetine has in particular beneficial effects on somatic symptoms of depression including pain. The superiority of duloxetine was shown over placebo, while comparison studies with other antidepressants showed only partial superiority. Randomized clinical trials in GAD also provide evidence for beneficial effects compared with placebo and improvement in quality of life, wellbeing and general health. Moreover, duloxetine is effective and well tolerated in the treatment of diabetic peripheral neuropathic pain and stress urinary incontinence. First results indicate that duloxetine might also be effective in the treatment of children with depression and pain. Overall, duloxetine is an interesting novel treatment option in the management of major depression and has shown efficacy in a broad range of diseases. It therefore may provide additional benefit to current therapeutic options in the treatment of psychiatric, internal, as well as urological disorders such as spinal dysfunctions. Due to duloxetine's properties, a wide range of use will be encountered in the mid-to-long term.
重度抑郁症(MDD)是最具致残性的疾病之一。目前,抗抑郁药物疗法在所有接受治疗的病例中约有70%有效;药理作用双重机制(如抑制血清素和去甲肾上腺素再摄取)的潜在优势广为人知。度洛西汀是一种新型的双重作用、选择性血清素和去甲肾上腺素再摄取抑制剂,已在治疗MDD和广泛性焦虑症(GAD)中显示出临床疗效。已发现度洛西汀安全且耐受性良好,不良事件为轻至中度,心血管和性功能障碍方面表现良好,对体重增加影响较小。度洛西汀治疗MDD的疗效已在随机、双盲、安慰剂对照研究中得到证实。除改善MDD的经典情绪症状外,度洛西汀对包括疼痛在内的抑郁躯体症状尤其有有益作用。度洛西汀显示出优于安慰剂,而与其他抗抑郁药的比较研究仅显示出部分优势。GAD的随机临床试验也提供了与安慰剂相比有益效果以及生活质量、幸福感和总体健康状况改善的证据。此外,度洛西汀在治疗糖尿病性周围神经病变疼痛和压力性尿失禁方面有效且耐受性良好。初步结果表明,度洛西汀在治疗伴有疼痛的儿童抑郁症方面可能也有效。总体而言,度洛西汀是重度抑郁症管理中一种有趣的新型治疗选择,已在广泛的疾病中显示出疗效。因此,它可能为当前治疗精神、内科以及泌尿外科疾病(如脊柱功能障碍)的治疗选择带来额外益处。由于度洛西汀的特性,从中长期来看将会有广泛的应用。